Prothena Q3 2026 net loss narrows to $16.5 million from $36.5 million a year earlier
Prothena reported third-quarter 2026 results with a net loss of $16.5 million, down from $36.5 million in the same quarter of 2025, while quarterly revenue fell to $0.6 million from $2.4 million. For the first nine months, revenue rose to $52.7 million, mainly from a $50.0 million milestone payment from Novo, and the net loss narrowed to $2.4 million from $222.5 million. The company said its 2026 net cash use and year-end cash guidance were unchanged.
Key points
- Q3 2026 net loss per share was $0.32, versus $0.68 in Q3 2025
- Nine-month 2026 revenue included a $50.0 million milestone payment from Novo tied to the coramitug Phase 3 trial
- Cash, cash equivalents and restricted cash were $272.2 million at September 30, 2026, with no debt
- Prothena repurchased $26.6 million of shares in the first nine months of 2026 under a $100.0 million program expiring December 31, 2026
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.